Melanoma is a common type of cancer. A clinical research study is evaluating an investigational drug (SEA-CD40) with other anti-cancer drugs to see if they work together to treat melanoma.

SEA-CD40 is a type of immunotherapy drug that binds to both cancer and immune cells that may help your immune system find and kill cancer cells. The use of SEA-CD40 described here is experimental. Because of that, not all risks are known. It is also not known if it will work in treating cancer. This is why we are conducting the study.

If you are interested in participating in the SGNS40-002 Study and have melanoma, please speak with a member of our study team.



The images depicted contain models and are being used for illustrative purposes only.

What is a clinical research study?

Clinical research studies are designed to investigate the effects of potential new medical treatments. The SGNS40-002 Study will help researchers learn more about the safety and effectiveness of the investigational drug, potentially providing a new treatment option for those with melanoma.

Participation in this clinical research study is completely voluntary. Participants who are eligible for the SGNS40-002 Study, and who choose to participate, may leave the study at any time without giving any reason.

Learn more about the SGNS40-002 Study

If you would like to learn more about the SGNS40-002 Study, or to schedule a visit to determine if you may be eligible to participate, please speak with your treating physician or the study physician.

Scan the QR code or please call 866-333-7436 if you would like more information on the SGNS40-002 Study.

Seagen®

SGNS40-002 – PFM – US Patient Brochure Melanoma – US/ENG – V1.0 – Nov2021
USM/S40/2021/0015

SGNS40 002 STUDY

Using immunotherapy to potentially fight cancer

Evaluating a combination therapy for melanoma

Seagen®

What is the SGNS40-002 Study?

The purpose of the SGNS40-002 Study is to test how well an investigational drug called SEA-CD40 works to treat melanoma when used with other drugs to treat cancer.

Who is eligible to participate?

You may be eligible to participate in the SGNS40-002 Study if you are age 18 or older and have:

- Melanoma that has not gotten better with treatment or has come back after treatment
- Uveal melanoma

If you are interested in joining the study, the study doctor will assess you to see if you meet further eligibility criteria.

Study Participation At-a-Glance

The study is divided into the following periods:

Screening Period (up to 4 weeks)

- The study doctor will do some tests and procedures to see if you qualify to be in the study.
- If you qualify to be in the study, you will start the Treatment Period.

Treatment Period

(42-day cycles for up to 2 years)

- You will receive SEA-CD40 on the first day and the 22nd day of each 42-day study cycle (one dose every 3 weeks).
- You will receive pembrolizumab on the 8th day of each 42-day study cycle (one dose every 6 weeks).

Follow-up Period (ongoing)

- You will have an End-of-Treatment visit about 30 days after your last dose.
- You will continue to have follow-up visits every 3 months until the study ends.
- If your cancer gets worse or you start a new cancer treatment, you may have follow-up phone calls until the study is closed.

You may stop participation at any time and for any reason. If you withdraw your consent to participate in the study, the study team will not contact you again.

The use of SEA-CD40 described here is experimental. Because of that, not all risks are known. It is also not known if it will work in treating cancer.

What should participants expect during the study?

Participants who would like to participate in the study will sign an Informed Consent Form. They will then have visits with the study doctor to determine if they are eligible to participate. This involves having some tests and procedures. If the study doctor determines a participant is eligible, and they choose to participate, they may begin the study.

- Participants will receive treatment in 42-day study cycles.
- All participants will receive SEA-CD40 and pembrolizumab in this study.

What is included in study participation?

All eligible study participants will receive the following at no cost:

- The investigational drugs, SEA-CD40 and pembrolizumab
- Study-related visits, assessments and tests

Participants may also be reimbursed for reasonable expenses, such as travel costs, for attending the study visits.

For more information about the investigational drug, tests or assessments, please speak with a member of the study team.